cilostazol has been researched along with Infarct, Lacunar in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 9.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia." | 9.19 | Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 5.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke." | 5.69 | Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial. ( Bamford, J; Bath, PM; Cvoro, V; Doubal, FN; England, T; Hassan, A; Heye, AK; Mhlanga, II; Montgomery, A; O'Brien, JT; Oatey, K; Roffe, C; Sprigg, N; Wardlaw, JM; Werring, DJ; Woodhouse, LJ, 2023) |
| "This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia." | 5.19 | Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently." | 2.84 | Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction. ( Abe, K; Fukui, Y; Hishikawa, N; Ohta, Y; Sato, K; Yamashita, T, 2017) |
| "The Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study showed a significant decrease in transcranial Doppler pulsatility index (PI) with cilostazol treatment after 90 days of acute lacunar infarction." | 2.82 | Serum Uric Acid Is Associated with Cerebral White Matter Hyperintensities in Patients with Acute Lacunar Infarction. ( Bushnell, CD; Han, SW; Kim, GS; Kim, OJ; Kim, SH; Koh, IS; Lee, JH; Lee, JY; Lee, KY; Lee, SI; Lee, SS; Nam, HS; Park, JH; Song, TJ; Suk, SH, 2016) |
| "Cilostazol was given to 63 patients (48." | 2.79 | Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study. ( Bushnell, CD; Han, SW; Kim, GS; Kim, JY; Kim, OJ; Kim, SH; Kim, WJ; Koh, IS; Lee, JH; Lee, JY; Lee, KY; Lee, SI; Lee, SS; Nam, HS; Park, JH; Song, TJ; Suk, SH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Bath, PM | 2 |
| Mhlanga, I | 1 |
| Woodhouse, LJ | 2 |
| Doubal, F | 1 |
| Oatey, K | 2 |
| Montgomery, AA | 1 |
| Wardlaw, JM | 2 |
| Hou, X | 1 |
| Cen, K | 1 |
| Cui, Y | 1 |
| Zhang, Y | 1 |
| Feng, X | 1 |
| Nishiyama, Y | 1 |
| Kimura, K | 1 |
| Otsuka, T | 1 |
| Toyoda, K | 1 |
| Uchiyama, S | 1 |
| Hoshino, H | 1 |
| Sakai, N | 1 |
| Okada, Y | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Minematsu, K | 1 |
| Matsumoto, M | 1 |
| Tominaga, T | 1 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 1 |
| Yamaguchi, T | 1 |
| Mhlanga, II | 1 |
| Heye, AK | 1 |
| Bamford, J | 1 |
| Cvoro, V | 1 |
| Doubal, FN | 1 |
| England, T | 1 |
| Hassan, A | 1 |
| Montgomery, A | 1 |
| O'Brien, JT | 1 |
| Roffe, C | 1 |
| Sprigg, N | 1 |
| Werring, DJ | 1 |
| Takase, B | 1 |
| Nagata, M | 1 |
| Hattori, H | 1 |
| Tanaka, Y | 1 |
| Ishihara, M | 1 |
| Han, SW | 3 |
| Song, TJ | 2 |
| Bushnell, CD | 2 |
| Lee, SS | 3 |
| Kim, SH | 3 |
| Lee, JH | 3 |
| Kim, GS | 3 |
| Kim, OJ | 3 |
| Koh, IS | 3 |
| Lee, JY | 3 |
| Suk, SH | 3 |
| Lee, SI | 3 |
| Nam, HS | 3 |
| Kim, WJ | 2 |
| Lee, KY | 3 |
| Park, JH | 4 |
| Kim, JY | 1 |
| Hishikawa, N | 1 |
| Fukui, Y | 1 |
| Sato, K | 1 |
| Ohta, Y | 1 |
| Yamashita, T | 1 |
| Abe, K | 1 |
| Yong, SW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study for the Multi-Center Placebo-Controlled Double-Blind Clinical Trial for the Evaluation of the Effect of Cilostazol on Pulsatility Index of Transcranial Doppler in the Acute Lacunar Infarction Patients[NCT00741286] | Phase 4 | 203 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00741286)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Asprin Plus Placebo | 1 |
| Asprin Plus Cilostazol | 1 |
The PI is designed to measure vascular resistance and characterizes the shape of the spectral waveform. For the study, the mean, systolic, and diastolic flow velocities were measured using TCD. Gosling's PI was determined as the difference between the peak systolic and end-diastolic velocities divided by the mean flow velocity in each artery.The changes of MCA and BA PIs at 14 and 90 days from the baseline TCD study was calculated for the study. (NCT00741286)
Timeframe: 14 days and 90 days from the baseline TCD study
| Intervention | ratio (Mean) | |||||
|---|---|---|---|---|---|---|
| Changes of PI in Right MCA (14 days) | Changes of PI in Right MCA (90 days) | Changes of PI in Left MCA (14 days) | Changes of PI in Left MCA (90 days) | Changes of PI in BA (14 days) | Changes of PI in BA (90 days) | |
| Asprin Plus Cilostazol | 0.08 | 0.14 | 0.1 | 0.13 | 0.09 | 0.18 |
| Asprin Plus Placebo | 0.07 | 0.09 | 0.08 | 0.07 | 0.09 | 0.1 |
1 review available for cilostazol and Infarct, Lacunar
| Article | Year |
|---|---|
Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Network Meta-Analysis; Platelet | 2023 |
8 trials available for cilostazol and Infarct, Lacunar
| Article | Year |
|---|---|
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
Topics: Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Middle Aged; Prospective | 2023 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2023 |
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Male; Middle Aged; Quality of Life | 2023 |
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug T | 2014 |
Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study.
Topics: Aged; Basilar Artery; Cilostazol; Double-Blind Method; Female; Humans; Leukoencephalopathies; Magnet | 2014 |
Serum Uric Acid Is Associated with Cerebral White Matter Hyperintensities in Patients with Acute Lacunar Infarction.
Topics: Aged; Cilostazol; Double-Blind Method; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging | 2016 |
Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.
Topics: Aged; Alzheimer Disease; Asymptomatic Diseases; Brain; Cholinesterase Inhibitors; Cilostazol; Cognit | 2017 |
Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mid | 2013 |